Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR) will post $26.00 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $23.60 million and the highest is $28.50 million. Nektar Therapeutics reported sales of $39.83 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 34.7%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 27th.
On average, analysts expect that Nektar Therapeutics will report full year sales of $106.99 million for the current financial year, with estimates ranging from $104.40 million to $110.00 million. For the next fiscal year, analysts forecast that the company will post sales of $150.30 million, with estimates ranging from $100.89 million to $205.71 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.17. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company had revenue of $29.22 million during the quarter, compared to the consensus estimate of $26.42 million. During the same period in the prior year, the company earned ($0.56) earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year.
Shares of Nektar Therapeutics stock traded down $0.25 during trading hours on Thursday, hitting $20.29. The company’s stock had a trading volume of 1,183,979 shares, compared to its average volume of 3,234,537. Nektar Therapeutics has a 12 month low of $15.64 and a 12 month high of $47.11. The stock has a 50 day moving average of $18.53 and a 200 day moving average of $24.92. The company has a market capitalization of $3.61 billion, a PE ratio of 5.37 and a beta of 2.62. The company has a debt-to-equity ratio of 0.26, a current ratio of 12.60 and a quick ratio of 12.49.
In related news, SVP Stephen K. Doberstein purchased 15,000 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was purchased at an average cost of $17.28 per share, for a total transaction of $259,200.00. Following the completion of the purchase, the senior vice president now directly owns 107,668 shares in the company, valued at $1,860,503.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $17.99, for a total value of $71,960.00. Following the completion of the transaction, the director now owns 276,973 shares of the company’s stock, valued at $4,982,744.27. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 175,178 shares of company stock valued at $3,738,898. 4.02% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Invesco Ltd. grew its stake in Nektar Therapeutics by 1,057.7% in the second quarter. Invesco Ltd. now owns 23,343,019 shares of the biopharmaceutical company’s stock valued at $830,544,000 after purchasing an additional 21,326,731 shares in the last quarter. Vanguard Group Inc. grew its stake in Nektar Therapeutics by 2.0% in the second quarter. Vanguard Group Inc. now owns 18,512,772 shares of the biopharmaceutical company’s stock valued at $658,684,000 after purchasing an additional 356,193 shares in the last quarter. BlackRock Inc. grew its stake in Nektar Therapeutics by 6.0% in the second quarter. BlackRock Inc. now owns 13,264,987 shares of the biopharmaceutical company’s stock valued at $471,969,000 after purchasing an additional 749,644 shares in the last quarter. State Street Corp grew its stake in Nektar Therapeutics by 3.9% in the third quarter. State Street Corp now owns 7,419,493 shares of the biopharmaceutical company’s stock valued at $135,146,000 after purchasing an additional 276,983 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in Nektar Therapeutics by 39.9% in the second quarter. First Trust Advisors LP now owns 3,005,999 shares of the biopharmaceutical company’s stock valued at $106,953,000 after purchasing an additional 856,819 shares in the last quarter. Hedge funds and other institutional investors own 99.77% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Recommended Story: FAANG Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.